Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue...
Drug safety advice*
- Tibolone (Livial): increased risk of breast cancer recurrence
- Non-steroidal anti-inflammatory drugs: cardiovascular risk
Yellow Card scheme update
- Reporting guidance
Stop press
- Toremifene (Fareston): risk of QT prolongation
- Methylphenidate: new guidance for use in treatment of ADHD
- Latest safety information online
- Correction: Temsirolimus—severe hypersensitivity reactions during infusion
Other information from the MHRA
- Patient Information Leaflet of the month: Actonel-Once-a-Week
- Consultation: measures to strengthen the medicines’ supply chain
* A Drug Safety Update summary leaflet that is inserted in the March 2009 edition of the British National Formulary mistakenly cites the February issue of the bulletin for further information on bisphosphonates and a risk of atypical stress fracture. In fact, this topic is included in the March 2009 issue of Drug Safety Update on page 8.
›
Drug Safety Update: Volume 2 Issue 8, March 2008
Drug Safety Update: Volume 2 Issue 7, February 2009 
